Table 2.
Immunohistochemistry results
| Patients |
Median percentage of TDLUs containing ALDH+ cells (range) |
||
|---|---|---|---|
| Luminal ductular level | Intermediate ductular level | Basal ductular level | |
| Pre-menopausal with family history of breast cancer, including patients with BRCA1 or BRCA2 mutation (n = 37) |
12 (0–62)** |
12 (0–53)** |
2 (0–18) |
| Pre-menopausal with BRCA1 mutation (n = 18) |
15 (2–50)* |
15 (6–38)* |
4 (0–18) |
| Pre-menopausal with BRCA2 mutation (n = 13) |
14 (0–62)* |
8 (2–53)* |
0 (0–18) |
| Pre-menopausal without family history of breast cancer (n = 25) |
6 (0–29) |
6 (0–44) |
0 (0–29) |
| Post-menopausal receiving HRT at the time of surgery (n = 7) |
10 (0–38)* |
8 (0–38)* |
2 (0–21) |
| Post-menopausal not receiving HRT at the time of surgery (n = 24) |
4 (0–32) |
4 (0–34) |
0 (0–18) |
| Nocancer, underwent mammoplasty (n = 34) | 6 (0–32) | 4 (0–44) | 0 (0–29) |
A statistical comparison of ALDH immunohistochemistry results for patients with and without a family history of breast cancer, and patients who were or were not receiving HRT at the time of surgery.
*P ≤ 0.05.
**P ≤ 0.01.
ALDH, aldehyde dehydrogenase 1 A1; TDLU, terminal duct lobular unit; HRT, hormone replacement therapy.